1-Year Comparative Effectiveness of Tofacitinib vs Ustekinumab for Patients With Ulcerative Colitis and Prior Antitumor Necrosis Factor Failure.
Rahul S DalalPuza P SharmaKanwal BainsJordan C PruceJessica R AllegrettiPublished in: Inflammatory bowel diseases (2023)
In a real-world UC cohort, tofacitinib and ustekinumab demonstrated similar effectiveness at 52 weeks. Adverse events were consistent with the known safety profiles of these agents.